Updating results

568 results

Sort: Relevance | Date

Lanadelumab for preventing recurrent attacks of hereditary angioedema [ID1268]

In development [GID-TA10333] Expected publication date: 09 October 2019

Technology appraisal guidance In development

Clostridium botulinum neurotoxin type A for treating hypersalivation associated with neurological conditions [ID1150]

In development [GID-TA10296] Expected publication date: 09 October 2019

Technology appraisal guidance In development

Decision making and mental capacity

In development [GID-NG10009] Expected publication date: 03 October 2018

NICE guideline In development

Nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer (CDF review TA484) [ID1572]

In development [GID-TA10513] Expected publication date: 29 January 2020

Technology appraisal guidance In development

Vagus nerve stimulation for treatment-resistant depression

In development [GID-IPG10133] Expected publication date: TBC

Interventional procedures guidance In development

Intravascular lithotripsy for calcified coronary arteries during percutaneous coronary intervention

In development [GID-IPG10132] Expected publication date: TBC

Interventional procedures guidance In development

Minimally invasive radical hysterectomy for early stage cervical cancer

In development [GID-IPG10131] Expected publication date: TBC

Interventional procedures guidance In development

High-sensitivity troponin for the early rule out of acute myocardial infarction (provisional title)

In development [GID-DG10035] Expected publication date: 08 April 2020

Diagnostics guidance In development

Functional electrical stimulation to improve muscle strength in non-neurological chronic conditions

In development [GID-IPG10135] Expected publication date: TBC

Interventional procedures guidance In development

Transcranial magnetic stimulation for obsessive-compulsive disorder

In development [GID-IPG10134] Expected publication date: TBC

Interventional procedures guidance In development

Crisaborole for treating mild to moderate atopic dermatitis in people aged 2 years and older (ID1195)

In development [GID-TA10435] Expected publication date: 03 June 2020

Technology appraisal guidance In development

Siponimod for treating secondary progressive multiple sclerosis [ID1304]

In development [GID-TA10436] Expected publication date: 03 June 2020

Technology appraisal guidance In development

Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours [ID1626]

In development [GID-TA10523] Expected publication date: TBC

Technology appraisal guidance In development

Insertion of an artificial iris implant for aniridia

In development [GID-IPG10130] Expected publication date: TBC

Interventional procedures guidance In development

Deep brain stimulation for refractory epilepsy

In development [GID-IPG10129] Expected publication date: TBC

Interventional procedures guidance In development

Cyanoacrylate glue occlusion for varicose veins

In development [GID-IPG10128] Expected publication date: TBC

Interventional procedures guidance In development

Ustekinumab for treating moderately to severely active ulcerative colitis [ID1511]

In development [GID-TA10434] Expected publication date: 04 March 2020

Technology appraisal guidance In development

Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]

In development [GID-TA10483] Expected publication date: TBC

Technology appraisal guidance In development

PneuX for preventing ventilator-associated pneumonia in intensive care

In development [GID-MT528] Expected publication date: 11 March 2020

Medical technologies guidance In development

Encorafenib with binimetinib and cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer

In development [GID-TA10479] Expected publication date: 22 July 2020

Technology appraisal guidance In development

Selinexor with low-dose dexamethasone for treating refractory multiple myeloma ID1535

In development [GID-TA10412] Expected publication date: 06 January 2021

Technology appraisal guidance In development

Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer ID1504

In development [GID-TA10400] Expected publication date: 11 December 2019

Technology appraisal guidance In development

Fedratinib for splenomegaly and symptoms in myelofibrosis [ID1501]

In development [GID-TA10406] Expected publication date: TBC

Technology appraisal guidance In development

PEGPH20 with nab-paclitaxel and gemcitabine for treating metastatic pancreatic cancer ID1502

In development [GID-TA10402] Expected publication date: TBC

Technology appraisal guidance In development

Carotuximab with pazopanib for treating advanced angiosarcoma ID1503

In development [GID-TA10401] Expected publication date: TBC

Technology appraisal guidance In development

KTE-C19 for previously treated B-precursor acute lymphoblastic leukaemia ID1494

In development [GID-TA10424] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab (Imfinzi) + Tremelimumab + standard chemotherapy for non-small cell lung cancer (NSCLC) lacking activating EGFR mutations and ALK fusions ID1538

In development [GID-TA10422] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency ID1498

In development [GID-TA10420] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab in combination for untreated, locally advanced or metastatic, triple negative breast cancer ID1546

In development [GID-TA10417] Expected publication date: TBC

Technology appraisal guidance In development

Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia ID1548

In development [GID-TA10416] Expected publication date: 02 December 2020

Technology appraisal guidance In development

Entrectinib for treating ROS1-positive locally advanced or metastatic non-small-cell lung cancer [ID1541]

In development [GID-TA10415] Expected publication date: 05 February 2020

Technology appraisal guidance In development

Pembrolizumab with chemotherapy for untreated extensive-stage small-cell lung cancer ID1509

In development [GID-TA10413] Expected publication date: TBC

Technology appraisal guidance In development

Budesonide for treating active eosinophilic oesophagitis [ID1202]

In development [GID-TA10372] Expected publication date: 08 July 2020

Technology appraisal guidance In development

Rezum for treating benign prostatic hyperplasia

In development [GID-MT529] Expected publication date: 06 April 2020

Medical technologies guidance In development

Meningitis (bacterial) and meningococcal septicaemia: recognition, diagnosis and management

In development [GID-NG10149] Expected publication date: 16 February 2022

NICE guideline In development

Thyroid cancer: assessment and management

In development [GID-NG10150] Expected publication date: 09 March 2022

NICE guideline In development

Nintedanib for treating interstitial lung disease caused by systemic sclerosis (ID1420)

In development [GID-TA10427] Expected publication date: TBC

Technology appraisal guidance In development

Faltering growth

In development [GID-QS10083] Expected publication date: 02 June 2020

Quality standard In development

Workplace health: long-term sickness absence and management

In development [GID-QS10114] Expected publication date: 13 January 2021

Quality standard In development

Community pharmacy: promoting health and wellbeing

In development [GID-QS10115] Expected publication date: 02 June 2020

Quality standard In development

Internal air: health effects

In development [GID-QS10113] Expected publication date: 20 October 2020

Quality standard In development

Elective joint replacement

In development [GID-QS10090] Expected publication date: 13 January 2021

Quality standard In development

Carers: provision of support for adult carers

In development [GID-QS10128] Expected publication date: 04 December 2020

Quality standard In development

Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]

In development [GID-TA10495] Expected publication date: 26 August 2020

Technology appraisal guidance In development

Fetal alcohol spectrum disorder

In development [GID-QS10139] Expected publication date: 31 July 2020

Quality standard In development

Trifluridine–tipiracil for treating metastatic gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID1507]

In development [GID-TA10456] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy ID1536

In development [GID-TA10466] Expected publication date: 15 January 2020

Technology appraisal guidance In development

Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after initial platinum-based chemotherapy [ID1518]

In development [GID-TA10504] Expected publication date: TBC

Technology appraisal guidance In development

Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]

Technology appraisal [TA582] Published date: 24 May 2019

Technology appraisal guidance In development